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cis-Diamminedichloroplatinum(II) (cisplatin or cis-[PtII(NH3)2(Cl)2]) 
with biological properties discovered serendipitously by Rosenberg in 1965 
and with approval given by the Food and Drug Administration in 1978 
went on to become an important clinically-used agent for the treatment 
of cancers [1]. This platinum drug together with its derivatives 
carboplatin and oxaliplatin are highly effective towards various kinds of 
cancers such as testicular cancer. Nevertheless, the toxic side effects of 
these platinum(II) complexes, including nephrotoxicity, emetogenesis 
and neurotoxicity, along with the wide range of cisplatin-resistant 
cancer cells, make them far from ideal drugs [2]. The tandem success 
and limitations of these platinum(II)-based drugs opened up a wealth 
of research into other classes of metal-based chemotherapeutic agents 
[3]. 
In view of the structural similarity, square-planar gold(III) 
complexes were thought to interact with DNA and other bio-
molecules in a way similar to that of the platinum(II)-based drugs. 
The gold(III) ion could covalently bind to methionine, ribonuclease A, 
and disulfides, and induce DNA strand breaks under physiologically-
relevant conditions [4]. Some cyclometalated gold(III) complexes with 
tridentate terpy ligands (wherein terpy = 2,2’:6’,2”-terpyridine) were 
found to interact with DNA via intercalation [5]. Several reports have 
revealed that gold(III) ion is capable to interact with small peptides or 
proteins such as human serum albumin, thioredoxin reductase and 
glutathione in vitro [4,6].
A dimethyl gold(III) complex was reported in early 1980s to display 
modest in vivo anti-cancer activities on mice bearing P388 leukemia 
[7]. This report subsequently triggered the anti-cancer studies of 
various gold(III) complexes containing monodentate or bidentate 
ligand(s). Many of these complexes were found to exhibit favorable in 
vitro anti-cancer properties with comparable cytotoxic activities to that 
of cisplatin [8]. Yet, the development of these gold(III) complexes as 
clinically-useful anti-cancer therapeutics had been severely hampered 
by their relatively poor stability under physiological conditions. The 
instability of gold(III) may also lead to the gold(I)-associated toxicity 
in vivo [9].
In 1996, a relatively stable gold(III) complex with tridentate damp 
ligand (wherein damp=2-[(dimethylamino)methyl]phenyl) has been 
found to display a moderate in vivo anti-tumor activity against human 
carcinoma xenografts [10]. Prompted by the result of this study, various 
highly anti-cancer active gold(III) complexes with tridentate bipyridyl 
ligands and dinuclear gold(III)-oxo complexes having a common 
Au2O2 motif which are stable in aqueous solutions have been identified 
[6]. Some gold(III) dithiocarbamate complexes have recently been 
found to significantly inhibit the tumor growth of MDA-MB-231 breast 
tumor-bearing mice associated with proteasome inhibition and massive 
apoptosis induction [11].
Apart from the stability issue, several factors including the high 
toxicity, induced drug resistance, poor cancer-cell specificity and 
limited bioavailability have also hampered the development of gold(III) 
complexes to be used clinically. Over the past decade, researchers 
have made enormous efforts to improve the anti-cancer efficacy of 
gold(III) complexes. The strategic approaches included the (1) use 
of multidentate ligands containing strong σ-donor atoms to stabilize 
gold(III) ion; (2) preparation of gold(III) complex possessing a net 
cationic charge to enhance cellular uptake efficacy; (3) introduction 
of cancer targeting group(s)/ hydrophilic substitution(s) to the ligand 
system; (4) encapsulation by polymeric substances to reduce the 
complex concentration under physiological conditions; (5) formation of 
dinuclear/ multinuclear gold(III) complexes to enhance their cytotoxic 
potencies; and (6) co-addition of cytotoxic agents to achieve synergism.
By using the robust porphyrinato ligand scaffold, a highly stable 
gold(III)-porphyrin complex system [AuIII(porphyrin)]+ possessing a 
net cationic charge was designed. The promising in vitro anti-cancer 
activities of a series gold(III) porphyrin complexes have been reported 
in 2003 [12]. In the subsequent studies, a drug lead [AuIII(TPP)]Cl 
(denoted as gold-1a, wherein H2TPP = meso-tetraphenyl porphyrin, 
(Figure 1) has been identified to display promising anti-tumor 
activities in various nude mice and rat models against hepatocellular 
carcinoma [13], colon cancer [14], neuroblastoma [15], melanoma [16], 
nasopharyngeal carcinoma (NPC) [17] and NPC-associated metastasis 
[18]. In a more recent study, the gold-1a was reported to block the 
self-renewal ability of cancer stem-like cells by regulating micro RNAs 
including miR-106a and miR-106b [19].
The acute toxicity of gold-1a on nude mice has been examined. 
Its LD50 value (median lethal dose) was determined to be 6.8 mg/kg 
(c.f. effective anti-cancer dosage ~ 3.0 mg/kg) [19]. One approach to 
reduce its toxicity is to prepare microcapsules of gold-1a; the sustained 
release gold-1a from the microcapsules could reduce the initial high 
complex concentration in biological system. Enhanced in vivo anti-
cancer property of gold-1a has been demonstrated by using polymeric 
encapsulating materials such as PEG [20] and mixture of gelatin and 
acacia [21]. More recently, the sustained-release property of gold-1a has 
also been demonstrated in an organo gold(III) supramolecular polymer 
Figure 1: Gold(III) porphyrin complex [AuIII(TPP)]Cl (gold-1a).
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containing [AuIII(C^N^C)(4-dpt)]+ moieties (wherein HC^N^CH 
= 2,6-diphenylpyridine; 4-dpt = 2,4-diamino-6-(4-pyridyl)-1,3,5-
triazine) [22]. 
One additional advantage for the medical development of the 
[AuIII(porphyrin)]+ system is the ease in structural modification of 
the gold(III) complexes. Over 25 gold(III) porphyrin complexes 
containing different substituents such as saccharide conjugation, 
lipophilic/ hydrophilic moieties have been prepared [23]. The biological 
properties including cytotoxicity, affinity to anti-apoptotic bcl-2 
protein, inhibition on thioredoxin reductase and topoisomerase were 
found to be significantly altered upon structural modification. In 2010, 
an asymmetrical gold(III) porphyrin analogue [5-(4-hydroxyphenyl)-
10,15,20-triphenylporphyrinato gold(III) chloride (gold-2a) was 
found to display promising in vivo anti-tumor activity towards breast 
carcinoma in nude mice xenografts [24].
Apart from the [AuIII(porphyrin)]+, another system of gold(III) 
complexes [AuIII(C^N^C)(NHC)]+ (wherein NHC=N-heterocyclic 
carbene) was also identified to have potent anti-cancer activities. 
A representative complex [AuIII(C^N^C)(IMe)]CF3SO3 (IMe=1,3-
dimethylimidazol-2-ylidene) was found to be stable under 
physiological conditions, to significantly poison topoisomerase I 
in vitro, and to suppress tumor growth in nude mice model [25]. 
Another series of cyclometalated gold(III) complexes [AuIIIm(C^N^C)
mL]n+ (m=1-3; n=0-3) was prepared by ligand substitution reaction 
of L with N-donor or phosphine ligands [26]. A dinucleargold(III) 
complex [AuIII2(C^N^C)2(μ-dppp)](CF3SO3)2 (Au3) (Figure 2) shows 
at least 100-fold higher cytotoxicity towards cancer cells in vitro than 
its monomeric gold(III) analogue [27]. Complex Au3 shows potent 
inhibition on hepatocellular tumor growth in nude mice and rat models 
with low acute and sub-chronic toxicities. Results from transcriptomics 
and connectivity map analyses have suggested that Au3 is a prominent 
inhibitor of thioredoxin reductase with an IC50 value as low as 2 nM, 
and also an inducer of endoplasmic reticulum (ER) stress. Meanwhile, 
treatment of Au3 on hepatocellular carcinoma cell line PLC was found 
to significantly enhance the expression of death receptor 5 (DR5). 
Understand the action mechanism of Au3 thus leads to the identification 
of cytotoxic TRAIL, a biological ligand for DR5, as a synergistic agent of 
the anti-cancer property of Au3 (Figure 2).
A number of gold(III) complexes have been reported to display 
promising in vitro anti-cancer activities and in vivo anti-tumor 
activities on various nude mice/ rat models over the past two decades. 
All these appealing activities, together with the feasibility in structurally 
modifying the gold(III) complexes to tune the biological activities, 
have highlighted the prospect in developing gold(III) complexes as 
promising anti-tumor therapy.
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Figure 2: Dinucleargold(III) complex [AuIII2(C^N^C)2(μ-dppp)](CF3SO3)2(Au3).
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